Source: European Medicines Agency (EU) Revision Year: 2025 Publisher: Sanofi Winthrop Industrie, 82 avenue Raspail, 94250 Gentilly, France
Kevzara 150 mg solution for injection in pre-filled syringe.
Kevzara 150 mg solution for injection in pre-filled pen.
Kevzara 200 mg solution for injection in pre-filled syringe.
Kevzara 200 mg solution for injection in pre-filled pen.
| Pharmaceutical Form |
|---|
|
Solution for injection (injection) Clear, colourless to pale yellow sterile solution of approximately pH 6.0. Kevzara 150 mg solution for injection: 298-346 mmol/kg. Kevzara 200 mg solution for injection: 306-371 mmol/kg. |
Kevzara 150 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 150 mg sarilumab in 1.14 ml solution (131.6 mg/ml).
Kevzara 150 mg solution for injection in pre-filled pen: Each pre-filled pen contains 150 mg sarilumab in 1.14 ml solution (131.6 mg/ml).
Kevzara 200 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 200 mg sarilumab in 1.14 ml solution (175 mg/ml).
Kevzara 200 mg solution for injection in pre-filled pen: Each pre-filled pen contains 200 mg sarilumab in 1.14 ml solution (175 mg/ml).
Sarilumab is a human monoclonal antibody produced in Chinese Hamster Ovary cells by recombinant DNA technology.
For the full list of excipients see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Sarilumab |
Sarilumab is a human monoclonal antibody (IgG1 subtype) that specifically binds to both soluble and membrane-bound IL-6 receptors (IL-6Rα), and inhibits IL-6-mediated signalling which involves ubiquitous signal-transducing glycoprotein 130 (gp130) and the Signal Transducer and Activator of Transcription-3 (STAT-3). In functional human cell-based assays, sarilumab was able to block the IL-6 signalling pathway, measured as STAT-3 inhibition, only in the presence of IL-6. |
| List of Excipients |
|---|
|
Histidine |
The pre-filled pen and pre-filled syringes contain a 1.14 ml solution in a syringe (type 1 glass) equipped with a stainless steel staked needle and an elastomer plunger stopper.
Kevzara 150 mg solution for injection in pre-filled syringe:
The single-use pre-filled syringe has a styrene-butadiene elastomer needle cap and is equipped with a white polystyrene plunger rod and a light-orange polypropylene finger flange.
Kevzara 200 mg solution for injection in pre-filled syringe:
The single-use pre-filled syringe has a styrene-butadiene elastomer needle cap and is equipped with a white polystyrene plunger rod and a dark-orange polypropylene finger flange.
Kevzara 150 mg solution for injection in pre-filled pen:
The syringe components are pre-assembled into a single-use pre-filled pen with a yellow needle cover and light-orange cap.
Kevzara 200 mg solution for injection in pre-filled pen:
The syringe components are pre-assembled into a single-use pre-filled pen with a yellow needle cover and dark-orange cap.
Pack sizes:
Not all pack sizes may be marketed.
Sanofi Winthrop Industrie, 82 avenue Raspail, 94250 Gentilly, France
EU/1/17/1196/001
EU/1/17/1196/002
EU/1/17/1196/003
EU/1/17/1196/004
EU/1/17/1196/005
EU/1/17/1196/006
EU/1/17/1196/007
EU/1/17/1196/008
EU/1/17/1196/009
EU/1/17/1196/010
EU/1/17/1196/011
EU/1/17/1196/012
Date of first authorisation: 23 June 2017
Date of latest renewal: 25 April 2022
| Drug | Countries | |
|---|---|---|
| KEVZARA | Austria, Canada, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.